Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB03 Afatinib
D09733 Afatinib dimaleate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Afatinib
D09733 Afatinib dimaleate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D09733 Afatinib dimaleate (USAN); Afatinib maleate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
DG00717 Afatinib
D09733 Afatinib dimaleate
Transporter substrate
DG01665 ABCB1 substrate
DG00717 Afatinib
D09733 Afatinib dimaleate
Drug classes [BR:br08332]
Antineoplastic
DG03162 EGFR inhibitor
D09733 Afatinib dimaleate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D09733 Afatinib dimaleate (USAN) <JP/US>
ERBB2 (HER2, CD340)
D09733 Afatinib dimaleate (USAN) <JP/US>
ERBB4 (HER4)
D09733 Afatinib dimaleate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09733
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09733
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09733
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09733
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D09733
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D09733
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
DG00717 Afatinib
Transporter substrate
DG01665 ABCB1 substrate
DG00717 Afatinib